Fred Kerwood
About Fred Kerwood
Fred Kerwood is a seasoned pharmaceutical executive with over 30 years of experience in program management and clinical operations, currently serving as the VP of Program Management.
Fred Kerwood Education and Expertise
Fred Kerwood holds an MBA in science and technology from LaSalle University and a Bachelor of Science degree in psychology/biochemistry from Texas A&M University. With over 30 years of experience in program management and clinical operations, he is well-versed in the pharmaceutical industry's complexities. His academic background provides a solid foundation for his extensive career in managing clinical trials and product development in the biopharmaceutical sector.
Fred Kerwood Background in the Pharmaceutical Industry
Fred Kerwood has built a robust career in the pharmaceutical industry, focusing on program management and clinical operations. Throughout his 30-year tenure, he has held key leadership roles at notable companies. Kerwood spent a decade at Johnson & Johnson, where he engaged in various roles related to program management, new product development, and strategic marketing. His extensive background highlights his versatility and expertise in navigating complex clinical and operational challenges.
Fred Kerwood Role at CytomX Therapeutics
As the VP of Clinical Operations at CytomX Therapeutics, Fred Kerwood oversaw the execution of oncology programs, including a significant Phase 2 program focusing on breast cancer. His leadership was crucial in advancing the company's clinical trials and ensuring regulatory compliance and operational efficiency. Kerwood's role at CytomX demonstrates his ability to steer large-scale clinical projects in an increasingly competitive and regulated industry.
Fred Kerwood Contributions at Immune Design, a Merck Subsidiary
Fred Kerwood served as the VP of Project Management and Clinical Operations at Immune Design, a subsidiary of Merck specializing in immuno-oncology. His responsibilities included managing the clinical operations and project timelines, which are vital for the successful development and commercialization of immune-based therapies. Kerwood’s experience at Immune Design underlines his capacity to lead complex clinical programs in innovative therapeutic areas.